最新心血管疾病预防PPT课件
《最新心血管疾病预防PPT课件》由会员分享,可在线阅读,更多相关《最新心血管疾病预防PPT课件(25页珍藏版)》请在装配图网上搜索。
1、心血管疾病预防心血管疾病预防Cardiovascular Deaths by Region in 1990:Global Burdon of Disease Study,1990PredictedDue to CHDDue to StrokeIncrease by 2002No.(x 106)(%)(%)(%)Established market economies3.2532515Former socialist economies2.1503126India2.35220111China2.6305077Other Asia and Islands1.33429106Sub-Saharan
2、 Africa0.82647114Latin America and Caribbean0.84432120Middle Eastern Crescent1.34716129Cardiovascular Deaths,1990Non Cigarette SmokersNon Cigarette SmokersAll Cigarette SmokersAll Cigarette Smokers10 010 0797911411464641221224444135135AnginaAnginaPectorisPectorisMyocardialMyocardialInfarctionInfarct
3、ionSuddenSuddenDeathDeathOBS.OBS.EXP.EXP.Summary of NCEP ATP III*Guidelines LDL-C Goals*National Cholesterol Education Program Adult Treatment Panel III.Therapeutic lifestyle changes include:(1)dietary changes:reduced intake of saturated fats and cholesterol and enhanced LDL lowering with plant stan
4、ols/sterols and increased soluble fiber;(2)weight reduction;and(3)increased physical activity.Coronary heart disease.CHD risk equivalents comprise:diabetes,multiple risk factors that confer a 10-year risk for CHD 20%,and other clinical forms of atherosclerotic disease(peripheral arterial disease,abd
5、ominal aortic aneurysm,and symptomatic carotid artery disease).Major risk factors(exclusive of LDL-C)that modify LDL-C goals include cigarette smoking,hypertension(BP 140/90 mmHg or on antihypertensive medication),low HDL cholesterol(40 mg/dL),family history of premature CHD(CHD in male first-degree
6、 relative 55 years;CHD in female first-degree relative 20%)100100130(100129:drug optional)2+Risk factors(10-year risk 20%)13013010-year risk 10%20%:13010-year risk 10%:16001 Risk factor160160190(160189:LDL-Clowering drug optional)Age*(years)Male(%)White(%)Body mass index*(kg/m3)Current smoker(%)Diab
7、etes(%)Hypertension(%)TC*(mg/dLmmol/L)LDL-C*(mg/dLmmol/L)TG*(mg/dLmmol/L)HDL-C*(mg/dLmmol/L)55.89.8719030.56.5262068231.834.2 6.00.9150.227.9 3.90.7197.295.7 2.21.242.39.9 1.10.3 CharacteristicAtorvastatin 80 mg(n=253)REVERSAL:Baseline Characteristics56.69.2738730.55.6271870232.634.1 6.00.9150.225.9
8、 3.90.7197.7105.6 2.21.142.911.4 1.10.3 Pravastatin 40 mg(n=249)*MeanSD*P0.001 vs pravastatinData are mean percent change from baseline to 18-month follow-up.-40-30-20-10010AtorvastatinChange From Baselinein Lipid Parameters-50Change from baseline(%)Total cholesterol LDL-cholesterol-25.2-18.45.6-6.8
9、-46.3*-34.1*2.9-20.0*Triglycerides HDL-cholesterolPravastatin4,162 4,162 patients with an Acute Coronary Syndrome 10 days patients with an Acute Coronary Syndrome 925 events)Duration:Mean 2 year follow-up(925 events)Primary Endpoint:Death,MI,Documented UA requiring hospitalization,Primary Endpoint:D
10、eath,MI,Documented UA requiring hospitalization,revascularization(30 days after randomization),or Stroke revascularization(30 days after randomization),or Stroke PROVE IT-TIMI 22:Study Design2 2x2 Factorial:Gatifloxacin vs.placebox2 Factorial:Gatifloxacin vs.placeboDouble-blindDouble-blindPatient po
11、pulation:CHDLDL-C:130-250 mg/dL(3.4-6.5 mmol/L)Triglycerides 600 mg/dL(6.8 mmol/L)Study DesignPrimary efficacy outcome measure:Time to occurrence of a major CV event:CHD deathNonfatal,non-procedure-related MIResuscitated cardiac arrestFatal or nonfatal strokeAtorvastatin 10 mgOpen-label run-inn=15,4
12、64 8 weeks1-8 weeksScreening and wash-outn=18,469Atorvastatin 10 mgLDL-C target:100 mg/dL(2.6 mmol/L)Median follow-up=4.9 yearsAtorvastatin 80 mgLDL-C target:75 mg/dL(1.9 mmol/L)Double-blind periodn=10,001LDL-C 130 mg/dL(3.4 mmol/L)n=4995n=5006BaselineAtorvastatin 10 mg(n=5006)Atorvastatin 80 mg(n=4
13、995)Age(mean SD),yearsMen(%)White(%)61 8.8819461 8.88194Cardiovascular risk factors(%)Current smokerHypertensionDiabetes mellitus135415135415Cardiovascular history(%)AnginaMICoronary angioplastyCoronary bypassCerebrovascular accident815854475825954475Baseline Patient CharacteristicsNo.of patients(%)
14、Atorvastatin 10 mg(n=5006)Atorvastatin 80 mg(n=4995)All-cause mortality282(5.6)284(5.7)CardiovascularCHD deathStroke deathHemorrhagic stroke death155(3.1)127(2.5)8(0.2)2(0.0)126(2.5)101(2.0)7(0.1)3(0.1)NoncardiovascularCancerTraumaOther127(2.5)75(1.5)9(0.2)43(0.9)158(3.2)85(1.7)15(0.3)58(1.2)No single cause of death(by body system,or pathological process)and no single cancer type drove the non-significant difference in all-cause mortality between groupsNo statistically significant differences were observed between treatment groups for any cause of deathMortality
- 温馨提示:
1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
2: 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
3.本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 装配图网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2020【企业咨询】行业前景分析投资调研课件
- 2020、6《民法典》资深律师解读宣讲课件
- 2020《推广普通话主题班会》课件
- 1205史剑波《纪昌学射》教学ppt课件
- 1981-1990诺贝尔生理或医学奖课件
- 2020【CDMO】行业前景分析投资调研课件
- 2020-2021年A股投资策略报告课件
- 2020【自助售货机】行业前景分析投资调研课件
- 刘姥姥进大观园PPT部编版9上课件
- 2020-2021年创新说课大赛获奖作品:教师说课比赛:等差数列课件
- 婚姻家庭与继承法课件
- 2020-2021年85、95后宝妈人群洞察课件
- 青少年的同伴关系
- 2020-2021年创新说课大赛获奖作品:教师说课比赛:等差数列的前n项和课件
- 青少年用眼健康知识讲解